Chronic myeloid leukemia is a clonal hematopoietic stem cell disorder. CML is caused by the BCR-ABL1 chimeric gene product, which results from a reciprocal balanced translocation between the long arms of chromosomes 9 and 22, t (9; 22) (q34.1; q11.2), known as the Philadelphia chromosome (Ph) and its codes for a constitutively active tyrosine kinase. CML is a common hematological malignancy in adults and accounts for 15% of all hematological malignancies. Worldwide incidence of CML is 1-2 cases per 1 lakh population per year. Material and Methods: This was a cross sectional, observational and Descriptive study conducted in tertiary care centre & teaching institute during the period from November 2018 to December 2020. Total 100 patients of Chronic Myeloid Leukemia irrespective of etiology were included in this study. Results: In our study most of the patients were aged between 31-40 years. Majority of the patients were males (62%) and male to female ratio was1.6:1. Generalized weakness was the most common symptom (52%) followed by fatigue (35%), pain in abdomen (22%), Anemia (46%) and splenomegaly (58%) & 16% of the patients were Asymptomatic. Among 100 CML cases, Chronic phase (CP) cases were 95%, Accelerated phase (AP) cases were 3%, Blast crisis (BC) cases were 2%. But majority of patients were in chronic phase (95%) which is a good sign as the disease is completely treatable in the modern era. Conclusion: CML accounts for one of the most common leukemia which is treatable with oral medications when presented at an early stage. TKIs have revolutionized the treatment of CML.

Chronic myeloid leukemia is a clonal hematopoietic stem cell disorder. CML is caused by the BCR-ABL1 chimeric gene product, which results from a reciprocal balanced translocation between the long arms of chromosomes 9 and 22, t (9; 22) (q34.1; q11.2), known as the Philadelphia chromosome (Ph) and its codes for a constitutively active tyrosine kinase. CML is a common hematological malignancy in adults and accounts for 15% of all hematological malignancies. Worldwide incidence of CML is 1-2 cases per 1 lakh population per year. Material and Methods: This was a cross sectional, observational and Descriptive study conducted in tertiary care centre & teaching institute during the period from November 2018 to December 2020. Total 100 patients of Chronic Myeloid Leukemia irrespective of etiology were included in this study. Results: In our study most of the patients were aged between 31-40 years. Majority of the patients were males (62%) and male to female ratio was1.6:1. Generalized weakness was the most common symptom (52%) followed by fatigue (35%), pain in abdomen (22%), Anemia (46%) and splenomegaly (58%) & 16% of the patients were Asymptomatic. Among 100 CML cases, Chronic phase (CP) cases were 95%, Accelerated phase (AP) cases were 3%, Blast crisis (BC) cases were 2%. But majority of patients were in chronic phase (95%) which is a good sign as the disease is completely treatable in the modern era. Conclusion: CML accounts for one of the most common leukemia which is treatable with oral medications when presented at an early stage. TKIs have revolutionized the treatment of CML.